The proteomics in prostate cancer biomarker discovery

Cover Page

Cite item

Full Text

Abstract

Prostate cancer (PC) represents the second most frequent type of tumor in men worldwide. Proteomics represents a promising approach for the discovery of new biomarkers able to improve the management of PC patients. Markers more specific and sensitive than prostate-specific antigen are needed for PC diagnosis, prognosis and response to treatment. Moreover, proteomics could represent an important tool to identify new molecular targets for PC tailored therapy. Now several possible PC biomarkers sources, each with advantages and limitations, are under investigation, including tissues, urine, serum, plasma and prostatic fluids. Innovative high-throughput proteomic platforms are now identifying and quantifying new specific and sensitive biomarkers for PC detection, stratification and treatment. Nevertheless, many putative biomarkers are still far from being applied in clinical practice.

This review aims to discuss the recent advances in PC proteomics, emphasizing biomarker discovery and their application to clinical utility for diagnosis and patient stratification.

About the authors

V. E. Shevchenko

N.N. Blokhin Russian Cancer Research Center

Author for correspondence.
Email: vshev@nm.ru
Research Institute of Carcinogenesis, 24 Kashirskoye Shosse, Moscow, 115478, Russia; 2 Russian Federation

A. V. Olenich

Medical Scientific Center “MedBioSpectr”

Email: fake@neicon.ru
24 bldg 8 Kashirskoye Shosse, Moscow, 115478, Russia Russian Federation

N. E. Olenich

N.N. Blokhin Russian Cancer Research Center

Email: fake@neicon.ru
24 Kashirskoye Shosse, Moscow, 115478, Russia; 2 Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.